TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20946966
Drug: Clofarabine (Clo)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (Clo) + Fludarabine (Flu) 10:30 mg/m²
Study: 20946966
Drug: Clofarabine (Clo)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (Clo) 40 mg/m²
Study: 20946966
Drug: Clofarabine (Clo)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (Clo) 20:20 mg/m²
Study: 20946966
Drug: Clofarabine (Clo)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (Clo) 30:10 mg/m²
Study: 20946966
Drug: Single-agent Clo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent Clo 40 mg/m²
Study: 19273465
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with usual care support
Study: 19273465
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with weekly support
Study: 9292621
Drug: Linopirdine (LPD)
Normalized name: linopirdine
DrugBank: Linopirdine (DB13806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linopirdine (LPD) 40 mg TID for 4 weeks
Study: 8328789
Drug: Spiramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin (1 g, orally, twice daily for 14 days)
Study: 8328789
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg, orally, twice daily for 14 days)
Study: 185885
Drug: Basal medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal medium (no lipolytic agents)
Study: 30132785
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 40,000 units subcutaneously weekly up to three doses or until ICU discharge
Study: 26078323
Drug: Killed whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole‐cell oral cholera vaccine (OCV)
Study: 23919622
Drug: ART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART plus FutureLife porridge nutritional supplement (NS) (388 kcal/day)
Study: 15058405
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene care regimen
Study: 11273790
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after oxygen (FiO(2)1.0)
Study: 11273790
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after hypoxic gas mixture (FiO(2)0.15)
Study: 26933398
Drug: HMB +
Normalized name: Hydroxymethylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB + Whey protein (3 g/day HMB and 36.6 g/day whey protein)
Study: 26933398
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (36.6 g/day)
Study: 25633712
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of 0.2% resiquimod gel (arm B)
Study: 25633712
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (arm A)
Study: 25633712
Drug: NY‐ESO‐1 protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: NY‐ESO‐1 protein plus Montanide with or without topical resiquimod
Study: 23074313
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Study: 23074313
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus dosing of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Study: 23074313
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus dosing of beta-lactam antibiotics
Study: 18333937
Drug: Oxytocin +
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin + ergometrine maleate 0.25 mg + oxytocin 20 iu
Study: 9257790
Drug: Inhaled lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine acetylsalicylate (LASA) 720 mg in 4 ml saline solution
Study: 30354558
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneously daily)
Study: 12800859
Drug: Flavoured water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoured water (0.1 g carbohydrate, Na+ 6 mmol x l(‐1))
Study: 12800859
Drug: Placebo (Na+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Na+ 2 mmol x l(‐1))
Study: 12800859
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (6.5% carbohydrate, 6.5 g carbohydrate, Na+ 21 mmol x l(‐1))
Study: 18328410
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution
Study: 6435484
Drug: TTS-nitroglycerin (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-nitroglycerin (transdermal therapeutic system)
Study: 6435484
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin ointment (0.5 inch applied at 8 hr intervals over 10 cm2 of skin)
Study: 24701539
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied in a single sitting divided into four sessions.
Study: 24701539
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control group (similar treatment without activating the LASER unit).
Study: 10629930
Drug: Amiridin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiridin (80 mg daily for 10 weeks)
Study: 10629930
Drug: Cerebrolysin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (20 intravenous infusions of 30 ml in 150 ml of physiologic solution during 4 weeks) followed by amiridin (80 mg daily for 10 weeks)
Study: 6101934
Drug: Beta-adrenoreceptor antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoreceptor antagonists (propranolol, oxprenolol, practolol, metoprolol, tolamolol)
Study: 28976976
Drug: 20-week prednisolone
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-week prednisolone treatment
Study: 28976976
Drug: 32-week prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32-week prednisolone treatment
Study: 19744006
Drug: D3 receptor
Normalized name: VITAMIN D3 RECEPTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 receptor subtype-selective agonists
Study: 12196433
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (40 mU/m2)
Study: 12196433
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (40 mU/m2)
Study: 2673622
Drug: Recainam (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (300 to 600 mg every 8 hours)
Study: 2673622
Drug: Recainam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (mean effective dosage 427 mg every 8 hours)
Study: 5420207
Drug: Oxazepam (Serenid-D)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (Serenid-D) in green tablets
Study: 5420207
Drug: Oxazepam (Serenid-D)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (Serenid-D) in yellow tablets
Study: 5420207
Drug: Oxazepam (Serenid-D)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (Serenid-D) in red tablets
Study: 30936281
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg or 90 mg
Study: 26248573
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate 110 mg b.i.d.
Study: 26248573
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate 150 mg b.i.d.
Study: 14571609
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI) 1.0 ml/kg
Study: 28029485
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI)
Study: 11230471
Drug: High-dose L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-asparaginase (HD ASP) arm; weekly intramuscular administration of HD ASP 25,000 IU/m² for a total of 20 weeks.
Study: 11230471
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SD ASP arm).
Study: 9692708
Drug: K‐Mag (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐Mag (70 mmol/day K, 35 mmol/day citrate and 17.6 mmol/day Mg)
Study: 7908130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dipyridamole with 1360 mg glutamic acid HCl (achlorhydric subjects)
Study: 7908130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dipyridamole without pretreatment (achlorhydric subjects)
Study: 7908130
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine (control subjects)
Study: 7908130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dipyridamole with 40 mg famotidine (control subjects)
Study: 7908130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dipyridamole (both groups)
Study: 2844492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drug and task performance
Study: 30672252
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with hydro-acupuncture (1 mL Danshen injection per point, 7 days per injection for 2 weeks)
Study: 30672252
Drug: Regular acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular acupuncture (once a day, six treatments per week for 2 weeks)
Study: 27427553
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) with T gel for 12 weeks, followed by cessation for 8 weeks
Study: 17051484
Drug: TNF-alpha antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha antagonists
Study: 417428
Drug: General supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: General supportive treatment
Study: 10966000
Drug: Four-day infusion
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-day infusion of fluorouracil (1000 mg/m2/day) plus vinorelbine (20 mg/m2/i.v. day 1 and 5), recycled every 3 weeks for a total of six courses.
Study: 25439417
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of intravenous (IV) melatonin
Study: 3163527
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (1% applied interdentally 4 times/year)
Study: 3163527
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (applied interdentally 4 times/year)
Study: 31150753
Drug: Psychosocial family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial family treatments during the first 9 months of the study
Study: 31150753
Drug: Baseline medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline medication exposure
Study: 25230094
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (afamelanotide + NB‐UV‐B)
Study: 25230094
Drug: NB‐UV‐B monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UV‐B monotherapy
Study: 21075452
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (BLT) for 6 weeks (10,000 lux, 30 min daily)
Study: 9018028
Drug: Sustained-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release carbidopa/levodopa (Sinemet CR 50/200)
Study: 9018028
Drug: Immediate-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa/levodopa (Sinemet 25/100)
Study: 3829588
Drug: 70 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mmol/l sucrose
Study: 3829588
Drug: 140 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mmol/l glucose
Study: 28108537
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels of 9-13 ng/L
Study: 28108537
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels of ≥14 ng/L
Study: 28108537
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels >8 ng/L
Study: 28108537
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels ≤5 ng/L
Study: 26291092
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for PAH
Study: 23147520
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily for 4 weeks
Study: 19169168
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of soy protein with 90 mg of isoflavones
Study: 19169168
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of soy protein without isoflavones
Study: 19169168
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of milk protein (casein and whey)
Study: 11431132
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with exogenous estrogen
Study: 11431132
Drug: Treatment aimed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment aimed at correcting metabolic abnormalities
Study: 9208356
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg daily for 3 months)
Study: 8215279
Drug: Monthly infusions
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly infusions of immune globulin at a dose of 500 mg/kg of body weight
Study: 2824045
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) 400 mg/m2 iv every 4 weeks until relapse
Study: 2824045
Drug: Iproplatin (CHIP)
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iproplatin (CHIP) 270 mg/m2 iv every 4 weeks until relapse
Study: 28419398
Drug: Ranibizumab (Lucentis;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (Lucentis; Genentech) - first intravitreal injection
Study: 19404172
Drug: Inpatient physical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient physical therapy program for 2 weeks
Study: 15451124
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) with intensive treatment
Study: 12053057
Drug: Betaxolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (20 mg)
Study: 8021483
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and dietary modification weight-loss programmes
Study: 2478793
Drug: Pimobendan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (5 mg b.i.d.)
Study: 973004
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of prostaglandin F2alpha
Study: 30782213
Drug: Levothyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine replacement therapy plus standard chronic heart failure treatment
Study: 30782213
Drug: Standard chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chronic heart failure therapy
Study: 28494046
Drug: Implant bed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant bed preparation before molar extractions
Study: 28494046
Drug: Implant bed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant bed preparation after molar extractions
Study: 17244178
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive therapy (ICT)
Study: 16236380
Drug: Fast-food Mediterranean
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-food Mediterranean type diet rich in PAF antagonist
Study: 1533606
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg)
Study: 3886498
Drug: Aspirin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Study: 3886498
Drug: Acetaminophen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Study: 3886498
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically packaged, 2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Study: 29797212
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin aspart (0.15 unit/kg every two hours)
Study: 29797212
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin (0.05-0.1 unit/kg/hour)
Study: 24286360
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release melatonin 2 mg (CRM)
Study: 15863532
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture closure alone
Study: 12195841
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation powder via Easyhaler (400 micrograms/day)
Study: 12195841
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation powder via Turbuhaler (400 micrograms/day)
Study: 9818662
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie diet, appetite suppressant, nonsteroidal antiinflammatory drugs, and walking program for 6 weeks
Study: 23053376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no medication
Study: 20724185
Drug: HRT preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT preparation (2 mg 17β-estradiol, E₂; 1 mg norethisterone acetate, NETA)
Study: 20724185
Drug: HRT preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT preparation (E₂ or NETA)
Study: 20724185
Drug: HRT preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT preparation
Study: 12803592
Drug: Intra-articular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular saline 10 ml
Study: 12803592
Drug: Intra-articular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular saline 10 ml with morphine 2 mg
Study: 1473916
Drug: Thrombolytic agent
Normalized name: Thrombolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agent alteplase
Study: 6464192
Drug: Oltipraz 2
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 2 X 20 mg/kg
Study: 6464192
Drug: Praziquantel 2
Normalized name: praziquantel 23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 2 X 30 mg/kg
Study: 6464192
Drug: Oltipraz 1
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 1 X 25 mg/kg
Study: 6464192
Drug: Oltipraz 1
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 1 X 35 mg/kg
Study: 31381847
Drug: CRA‐melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA‐melatonin (5 mg)
Study: 31381847
Drug: IR‐melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐melatonin (5 mg)
Study: 29779247
Drug: POLLINEX® Quattro
Approvals — FDA: no, EMA: no, PMDA: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (cumulative doses ranging from 5100 to 27300 SU)
Study: 29779247
Drug: POLLINEX® Quattro
Approvals — FDA: no, EMA: no, PMDA: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (highest cumulative dose of 27300 SU)
Study: 29779247
Drug: POLLINEX® Quattro
Approvals — FDA: no, EMA: no, PMDA: no
Description: POLLINEX® Quattro Plus 1.0 ml Birch 100% (various active doses)
Study: 18852657
Drug: Steroids (S)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (S)
Study: 18852657
Drug: Steroids (S)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (S) in hepatitis C virus patients
Study: 12051959
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at a dose of 2 g/day